Sandoz, Taiwan’s TLC Ink Commercialization Deal For AmBisome Generic In U.S., EU
This article was originally published in PharmAsia News
Executive Summary
Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.